TARS Insider Buying
The table below summarizes the most recent TARS insider buying information — the latest buy being $18,960.00 by Andrew D. Goldberg on 12/15/2023, with links to see the CAGR achieved by each insider on their purchases. As the saying goes on Wall Street, there are many possible reasons to sell a stock, but only one reason to buy. Watch the importance of insider buying video for more information about why TARS insider buys like these are important for investors to follow.
| Date | Insider | Price | Amount |
|---|---|---|---|
| 12-15-2023 Insider Buy |
Andrew D. Goldberg Director |
$18.96 CAGR » |
$18,960.00 1,000 shares |
| 8-15-2023 Insider Buy |
Elizabeth Yeu Lin Director |
$16.80 CAGR » |
$159,700.80 9,506 shares |
| 5-5-2022 Insider Buy |
Michael Ackermann Director |
$13.50 CAGR » |
$1,350,000.00 100,000 shares |
| 10-20-2020 Insider Buy |
Jason E. Tester Director and >10% Owner |
$16.00 CAGR » |
$2,750,000.00 171,875 shares |
| 10-20-2020 Insider Buy |
Vivo Capital IX, LLC >10% Owner |
$16.00 CAGR » |
$4,000,000.00 250,000 shares |
| 10-20-2020 Insider Buy |
Limited Partnership Viii Horowitz >10% Owner |
$16.00 CAGR » |
$2,950,000.00 184,375 shares |
| 10-20-2020 Insider Buy |
Frazier Life Sciences IX, L.P. >10% Owner |
$16.00 CAGR » |
$5,000,000.00 312,500 shares |
Also See: SEC filings
Tarsus Pharmaceuticals Insider Purchase CAGR Analysis
|
Growth of $10,000.00 Without Dividends Reinvested |
||
| Start date: | 12/18/2023 | |
| End date: | 09/04/2026 | |
| Start price/share: | $18.98 | |
| End price/share: | $90.78 | |
| Dividends collected/share: | $0.00 | |
| Total return: | 378.29% | |
| Average Annual Total Return: | 78.07% | |
| Starting investment: | $10,000.00 | |
| Ending investment: | $47,828.25 | |
| Years: | 2.71 | |
